The reason behind the memorandum of understanding with the Hong Kong-Shenzhen Science and Technology Innovation Park is a concrete reflection of China's biotechnology services speeding up the commercialization process of boron neutron capture therapy.
On April 18, China Biotechnology Service (08037) announced that it had signed a memorandum of understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited (“Hong Kong-Shenzhen Science and Technology Innovation Park Company”) and held a partner launch ceremony at the Hong Kong-Shenzhen Science and Technology Innovation Park.
According to the memorandum of understanding, the Hong Kong-Shenzhen Science and Technology Innovation Park plans to introduce a boron neutron capture therapy program. Mesochem Services will jointly build a BNCT Hetao treatment center with Japan's Sumitomo Heavy Industries Machinery Co., Ltd. and Japanese boron medicine company Stella Pharma Co., Ltd. in the Hetao region of Hong Kong.
The Hong Kong-Shenzhen Innovation and Technology Park is a Hong Kong park in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. With its geographical advantages, it will become an important platform for innovation and technology cooperation with the mainland. It will help promote Hong Kong's integration into national development, and benefit the Hong Kong-Shenzhen Innovation and Technology Park partners and the entire innovation and technology community. The introduction of a boron neutron capture therapy project is also an optimism of the Hong Kong-Shenzhen Innovation and Science Park about the development prospects of this therapy.
The Zhitong Finance App learned that China's biotechnology services are progressing steadily as expected in accelerating the commercialization of their CAR-T business and boron neutron treatment centers. Its Pengbo Boao Boron Neutron Hospital, located in the Boao Lecheng International Medical Tourism Pilot Zone, was fully capped in December 2023 as expected. Installation of equipment has now begun. It is expected that it will start operating and receiving patients from the end of 2024 to the beginning of 2025.
The reason behind the memorandum of understanding with the Hong Kong-Shenzhen Science and Technology Innovation Park is a concrete manifestation of its speeding up the commercialization process of boron neutron capture therapy. This marks that Mesoscience will become the first company to open a boron neutron capture treatment center in Hong Kong. This will lay the foundation for its future use of regional advantages to serve cancer patients in Hong Kong, the Greater Bay Area, Southeast Asia and South Asia.
Meanwhile, Shanghai Longyao Biology, a subsidiary of China Biotechnology Service, is conducting clinical trials at Shanghai Ruijin Hospital and Jiangsu Provincial People's Hospital, and will announce the latest clinical research data on LY007 cell injections targeting CD20 CAR-T products at the 2024 ASCO annual meeting.
In recent years, China Biotechnology Service has been committed to building an advanced biotechnology platform integrating cancer diagnosis and treatment. It has laid out the three major fields of accurate diagnosis, CAR-T cell therapy, and BNCT boron neutron therapy, and has achieved leading regional or international advantages. With the acceleration of the first phase clinical development of the company's CAR-T business and the rapid commercialization of boron neutron therapy, China's biotechnology services will usher in a time of value fission.